Mr. Enright is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Mr. Enright was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice. Prior to Pequot, he was a Managing Member of the Delta Opportunity Fund at Diaz & Altschul Capital Management. Mr. Enright began his investment career at PaineWebber Development Corporation. Mr. Enright also has significant life sciences operations experience, including senior executive positions at Valentis, Boehringer Mannheim (acquired by Roche) and Sandoz (now known as Novartis). Mr. Enright currently serves on the board of directors of BioAge Labs, Inc., and Zenas Biopharma, Inc. as well as several private companies, including as Chair of CuraSen Therapeutics, Inc.
Selected prior public company board memberships include Aptinyx Inc., Aimmune Therapeutics, Inc., (acquired by Nestlé Health Science in October 2020), Codexis, Inc., Corcept Therapeutics, Inc., Esperion Therapeutics, Inc., Horizon Pharma plc and Threshold Pharmaceuticals, Inc. Mr. Enright holds an MBA from the Wharton School of Business at the University of Pennsylvania and a BS in Biological Sciences from Stanford University.
What is Patrick G. Enright's net worth?
The estimated net worth of Patrick G. Enright is at least $510.89 thousand as of October 9th, 2025. Mr. Enright owns 11,990 shares of Vera Therapeutics stock worth more than $510,894 as of December 4th. This net worth estimate does not reflect any other assets that Mr. Enright may own. Learn More about Patrick G. Enright's net worth.
How do I contact Patrick G. Enright?
Has Patrick G. Enright been buying or selling shares of Vera Therapeutics?
Patrick G. Enright has not been actively trading shares of Vera Therapeutics in the last ninety days. Most recently, on Tuesday, June 24th, Patrick G. Enright bought 40,607 shares of Vera Therapeutics stock. The stock was acquired at an average cost of $22.35 per share, with a total value of $907,566.45. Following the completion of the transaction, the director now directly owns 3,596,593 shares of the company's stock, valued at $80,383,853.55. Learn More on Patrick G. Enright's trading history.
Who are Vera Therapeutics' active insiders?
Are insiders buying or selling shares of Vera Therapeutics?
In the last year, Vera Therapeutics insiders bought shares 2 times. They purchased a total of 250,000 shares worth more than $5,277,598.36. In the last year, insiders at the sold shares 4 times. They sold a total of 67,500 shares worth more than $2,741,525.00. The most recent insider tranaction occured on November, 11th when SVP Joseph R Young sold 15,000 shares worth more than $435,900.00. Insiders at Vera Therapeutics own 16.3% of the company.
Learn More about insider trades at Vera Therapeutics. Information on this page was last updated on 11/11/2025.
